Search 

Sinovant Sciences (http://www.sinovant.com) is an innovative biopharmaceutical company based in Shanghai, Beijing and Hong Kong. Sinovant was founded by Chinese scientists and physicians, including Chinese “Returnees”. Sinovant is uniquely positioned to bring cutting-edge global medical innovation to China, and transformative Chinese medical innovation to the world.  

   

Sinovant has a diverse pipeline of 11 investigational products in development, among which 5 drug candidates are in phase III or beyond. Our products span over 6 therapeutic areas including oncology, infectious disease, urology / nephrology, gastrointestinal diseases, dermatology and rare diseases. 

SYNSIGHT developed the first drug discovery platform combining cell-based microscopy that train AI models, to generate new chemical entities. Your benefits will be to increase the productivity of your R&D and secure your drug discovery programs.

Our innovative platform and our technologies can be directly applied to protein-protein or protein-RNA interactions. Our bioassay is unique and patented and is able to qualify and quantify these interactions directly in human cell, and also of course the efficacy of small molecule modulators (Hit identification, "in cell IC50" measurement). This assay, easy to setup as medium or high-throughput screening level, is then able to train our AI models which generate new molecules.

We already successfully used our platform to study oncologic and neurodegenerative targets, for our own R&D or for customers. Our platform is able to manage different therapeutic area (oncology, virology, neurology, …), and different targets from your portfolio. We also propose to feed your portfolio and develop screening setup of our platform with exclusivity, with innovative targets like TPD-43, YB-1, alpha-SYN, BCL2, HUR, …

VC investment focus on healthy care

Usurpo are a UK based specialist search firm focused on helping high-growth Life Sciences businesses hire outstanding executives worldwide. We have successfully run search campaigns in EMEA, ASIA PAC, India and the US.

We work closely with Pharmaceutical, Biotechnology, Medical Device companies and service providers to help them build exceptional leadership teams, particularly across Europe and the US. We have a track record of helping international business from China, Japan, Israel and Korea make key hires in the US and Europe for their expanding international teams.

We help our clients to hire Senior Director, VP and C-suite level professionals into the following areas:

- Clinical Development (Chief Medical Officer, Chief Development Officer, Medical Director, Therapeutic area experts)
- Regulatory Affairs
- CMC
- Business Development (Licensing, M&A, Corporate Development)
- Business Development (Sales and business expansion for service providers)
- Cross functional C-suite leadership
- Sales and Marketing leaders

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

Listed in China Growth Board, WolwoPharma is the biggest allergen drug manufacturer in China
and the largest allergen preparation supplier in Asia.

Xuanzhu Biopharmaceutical was founded in 2002. In 2012, it became a wholly-owned subsidiary of Sihuan Pharmaceutical. In 2018, Xuanzhu Biopharmaceutical spun-off and became independent, with a registered capital of RMB1.15 billion. Different from other emerging unprofitable biotechnology companies, Xuanzhu Biopharmaceutical is one of the few domestic innovative drug companies with a complete research and development industry chain. It has not only more than a dozen innovative R&D products, but also support from a leading domestic pharmaceutical company in Sihuan Pharmaceutical. With strong production and commercialization capabilities, Xuanzhu Biopharmaceutical possesses the potential of becoming an international enterprise integrating R&D, manufactuing and marketing platforms.

healthcare VC

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services

2nd market PE,
about 300M RMB total value,
mainly focus on A-share market and startup on H-share market,
concentrating on high-speed developing industrials especially in Healthcare, including Big Biopharma/Superior Biotech companies.